References
- Kaufmann M, Maass N, Costa SD et al. First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial. Eur. J. Cancer46, 3184–3191 (2010).
- O’Shaughnessy JA, Blum J, Moiseyenko V et al. Randomized, open-label, Phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann. Oncol.12, 1247–1254 (2001).
- Minea L, Stanculeanu DL, Cringeanu A et al. Capecitabine monotherapy for elderly patients with metastatic breast cancer. J. Clin. Oncol. ASCO Annual Meeting Proceedings22(Suppl. 14), 76s (2004).
- Bajetta E, Procopio G, Celio L et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J. Clin. Oncol.23, 2155–2161 (2005).
- Stockler M, Sourjina T, Grimison P et al. A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC). J. Clin. Oncol. ASCO Annual Meeting Proceedings25, 1031 (2007).
- Piccart-Gebhart MJ, Burzykowski T, Buyse M et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J. Clin. Oncol.26, 1980–1986 (2008).
- Talbot DC, Moiseyenko V, Van Belle S et al. Randomised, Phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br. J. Cancer86, 1367–1372 (2002).
- Blum JL, Jones SE, Buzdar AU et al. Multicenter Phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J. Clin. Oncol.17, 485–493 (1999).
- Blum JL, Dieras V, Lo Russo PM et al. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer92, 1759–1768 (2001).
- Reichardt P, Von Minckwitz G, Thuss-Patience PC et al. Multicenter Phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann. Oncol.14, 1227–1233 (2003).
- Fumoleau P, Largillier R, Clippe C et al. Multicentre, Phase II study evaluation capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur. J. Cancer40, 536–542 (2004).
- Blum JL, Jones SE, Buzdar AU; on behalf of the Xeloda Breast Cancer Study Group. Capecitabine in 162 patients with paclitaxel-pretreated MBC: updated results and analysis of dose modification. Eur. J. Cancer37(Suppl. 6), 190 (2001).
- Rossi D, Alessandroni P, Catalano V et al. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer. Clin. Breast Cancer7, 857–860 (2007).
- Zielinski C, Gralow J, Martin M. Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed? Ann. Oncol.21, 2145–2152 (2010).
- Kusama M, Nomizu T, Aogi K et al. Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer. Breast Cancer17, 233–240 (2010).
- Saeki T, Kimura T, Toi M, Taguchi T. A pilot Phase II study of capecitabine in advanced or recurrent breast cancer. Breast Cancer13, 49–57 (2006).
- Taguchi T, Nakayama T, Masuda N et al. Study of low-dose capecitabine monotherapy for metastatic breast cancer. Chemotherapy56, 166–170 (2010).
- Martin M, Calvo L, Martinez N et al. Randomized, Phase II trial comparing continuous versus intermittent capecitabine monotherapy for metastatic breast cancer (MBC). J. Clin. Oncol.27(15 Suppl.), 1086 (2009).
- Traina TA, Theodoulou M, Feigin K et al. Phase I study of a novel capecitabine schedule based on the Norton–Simon mathematical model in patients with metastatic breast cancer. J. Clin. Oncol.26, 1797–1802 (2008).
- Blum JL, Kohles J, McKenna E et al. Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials. Breast Cancer Res. Treat.125(2), 431–439 (2010).